Grounding the Excitement of Psychedelics: Developing Non-Hallucinogenic Compounds That Are Commercially Viable
Time: 12:30 pm
day: Track 2 AM Day 2
Details:
- Developing therapeutics that will be embraced by mainstream payers and realistically adopted by pharmaceutical companies
- Considerations for patient adoption: eliminating the psychotropic acute phase of their dosing
